The Oticon Intent is a premium prescription behind-the-ear hearing aid released in 2024, earning an A grade and the top rank among all 34 prescription hearing aids tested by HearAdvisor. At $4,898, it sits in the highest price tier but delivers sound performance that justifies its positioning for users prioritizing speech understanding.
In our lab testing, the Intent demonstrated exceptional strength in speech intelligibility. Its speech-in-noise performance measured 2.18 points above the category average—a substantial margin that places it among the best performers for challenging listening environments like restaurants or group conversations. Speech in quiet also exceeded average by 1.19 points, indicating strong overall clarity.
The device does have a notable weakness: own-voice comfort scored 1.46 points below average, which relates to occlusion effects that can make your own voice sound boomy or unnatural. This is worth discussing with your hearing care provider, particularly if own-voice quality is a priority. Music streaming quality, however, performed well above average, making this a solid choice for users who frequently stream audio from their phones.
Compared to similarly priced competitors like the Phonak Sphere Infinio ($4,398) and Signia Active Pro IX, the Intent edges ahead in overall sound performance while offering rechargeable batteries and streaming compatibility with both iPhone and Android devices. The Oticon Intent is best suited for users who prioritize speech understanding in difficult listening situations and can work with their provider to address potential own-voice concerns.
